Our top pick for
ALX Oncology Holdings Inc is a biotechnology business based in the US. ALX Oncology shares (ALXO) are listed on the NASDAQ and all prices are listed in US Dollars. ALX Oncology employs 29 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$54.88|
|52-week range||$38.09 - $110.00|
|50-day moving average||$72.01|
|200-day moving average||$63.49|
|Wall St. target price||$98.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.62|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-7.76%|
|1 month (2021-09-21)||-27.79%|
|3 months (2021-07-21)||-6.00%|
|6 months (2021-04-21)||-5.38%|
|1 year (2020-10-21)||28.55%|
|2 years (2019-10-17)||N/A|
|3 years (2018-10-17)||N/A|
|5 years (2016-10-17)||N/A|
|Gross profit TTM||$107,000|
|Return on assets TTM||-13.86%|
|Return on equity TTM||-23.97%|
|Market capitalisation||$2.4 billion|
TTM: trailing 12 months
There are currently 2.3 million ALX Oncology shares held short by investors – that's known as ALX Oncology's "short interest". This figure is 6.7% down from 2.5 million last month.
There are a few different ways that this level of interest in shorting ALX Oncology shares can be evaluated.
ALX Oncology's "short interest ratio" (SIR) is the quantity of ALX Oncology shares currently shorted divided by the average quantity of ALX Oncology shares traded daily (recently around 185000.64516129). ALX Oncology's SIR currently stands at 12.4. In other words for every 100,000 ALX Oncology shares traded daily on the market, roughly 12400 shares are currently held short.
However ALX Oncology's short interest can also be evaluated against the total number of ALX Oncology shares, or, against the total number of tradable ALX Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ALX Oncology's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 ALX Oncology shares in existence, roughly 60 shares are currently held short) or 0.1323% of the tradable shares (for every 100,000 tradable ALX Oncology shares, roughly 132 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against ALX Oncology.
Find out more about how you can short ALX Oncology stock.
We're not expecting ALX Oncology to pay a dividend over the next 12 months.
ALX Oncology Holdings Inc. , a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.